Link to paper Bhattacharya A, Bense RD, Urzúa-Traslaviña CG, de Vries EGE, van Vugt MATM, Fehrmann RSN AbstractCopy number alterations (CNAs) can promote tumor progression by altering gene expression levels. Due to transcriptional adaptive mechanisms, however, CNAs do not always translate proportionally into altered expression levels. By reanalyzing >34,000 gene expression profiles, we reveal the…
Link to paper van de Donk PP, Kist de Ruijter L, Lub-de Hooge MN, Brouwers AH, van der Wekken AJ, Oosting SF, Fehrmann RSN, de Groot DJA, de Vries EGE Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the…
Working environment “Using machine learning to unravel the ‘cancer-immune setpoint’ in cancers.” We have an exciting opportunity for a PhD student. The position will be for 4 years and should results in a PhD thesis at the University of Groningen. The PhD student position is available in the research group of dr. Rudolf Fehrmann. The…
Link to paper J.S. Hooiveld-Noeken, R.S.N. Fehrmann, E.G.E. de Vries, M. Jalving Highlights • Metastatic Merkel- and cutaneous squamous cell carcinoma are rare tumours. • Immunotherapy gives impressive responses but most patients do not survive long-term. • Small patients numbers prevent extensive biomarker research in clinical trials. • Pooled data from common and rare tumours…
On Wednesday November 20th, Rico Bense successfully defended his PhD thesis. See the summary description of his thesis below: In clinical practice, breast cancer is currently divided into subtypes based on immunohistochemical expression of the estrogen receptor and human epidermal growth factor receptor 2. These subtypes are crucial for treatment choice and outcome. However, even…
14th of November I gave an oral presentation at the 25th Oncologiedagen voor Nederland en Vlaanderen, Arnhem, the Netherlands. Below is the link to PDF with the slide presented. 2019-NVMO_OncologieDagen.pdf
Last Friday I received an email with some great news 🙂 The Scientific Advisory Board and the Board of the Hanarth Fonds have decided that 6 candidates are eligible for funding of their proposal. The quality of the proposals was very good and we are happy to inform you that your proposal has been selected…
The Medical Oncologist perspective With great pleasure I chaired the session “What s the future role of artificial intelligence in medical oncology?” at the European Society for Medical Oncology (ESMO) congress 2019. Also good to see so many people attending this session. For those that are interested in the presentation, I provide the presentation here.…
Link to paper Peters MAM, Meijer C, Fehrmann RSN, Walenkamp AME, Kema IP, de Vries EGE, Hollema H, Oosting SF. Abstract In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour set…
Today I agreed to take on the role of an associate editor for Cancer Genetics in Frontiers in Genetcs and Frontiers in Oncology. As an Associate Editor, I will actively contribute to the strategic development of the section and ensure its quality through overseeing the review process of manuscripts. This is a nice opportunity for…